case_images: PMC10829570_01
case_images: (A-C) Disease imaging (CT-scan). (A) Disease status at diagnosis. (B) Disease status at the time of bicalutamide start. (C) Disease status after 32 months of bicalutamide therapy. CT, computed tomography.
case_images: fonc-13-1260668-g001.jpg
case_images: PMC10829570_01_fonc-13-1260668-g001.jpg
case_images: f1
case_images: The initial size of the perineal lesion was 10x9x13 cm ( Figure 1A ), with a disease stability lasting about 12 months during watchful waiting. After three months of treatment (March 2020), the patient underwent a new CT scan, which documented further disease progression ( Figure 1B ). Periodic (every 3-4 months) imaging assessments with abdominal and thoracic CT scan were performed, documenting a substantial radiological stability, confirmed at the last follow-up of December 2022, 32 months since the start of bicalutamide therapy ( Figure 1C ).
case_images: Timeline p.o, per os; SD, stable disease; PD, progressive disease; ong, ongoing.
case_images: fonc-13-1260668-g002.jpg
case_images: PMC10829570_01_fonc-13-1260668-g002.jpg
case_images: f2